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CHAPTER 1 
BACKGROUND 
The goal of this capstone is to highlight the use of publicly available complex sample public 
health data like the National Health and Nutrition Examination Survey (NHANES) and the 
Behavioral Risk Factor Surveillance System (BRFSS) to address relevant public health questions 
in the topics of environmental health and health policy using epidemiologic methods.  
The role of the first paper on environmental health is to assess the role of blood 
manganese levels on myocardial infarction, stroke, and renal dysfunction and explore differences 
based on socioeconomic status. This paper will quantify the association of blood manganese 
levels and also provide information on individual and socioeconomic factors that are related to 
myocardial infarction, stroke, and renal dysfunction. Due to the lack of US studies this, the 
present analyses will fill some of the knowledge gaps from previous studies that were primarily 
conducted in Asia and Europe.  
The second paper using the health policy perspective will describe the impact of the 
Affordable Care Act (2010) on current smoking and quit-attempts among expanded and non-
expanded US states, and identify the impact among low-income individuals, and examine the 
state-level barriers to smoking cessation services in the expanded and non-expanded states.  
The capstone will be divided into two separate papers that will include the introduction, 
methods, results, discussion sections of the two distinct topics of environmental health and health 
policy. Lastly, the conclusion will highlight the recommendations and the public health 
implications for the two papers. 
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ABSTRACT  
Introduction: Manganese is an essential trace element that can cause adverse health effects with 
deficiency and in excess amounts. The purpose of this study is to determine the asscociation of 
blood manganese levels and the prevalence of myocardial infarction, stroke, and renal 
dysfunction in a general US population.  
Methods: Data were used from the National Health and Nutritional Examination Survey 
(NHANES) of non-institutionalized US adults 20 years and older using the 2011-2012, 2013-
2014, and 2015-2016 survey cycles (n=16629). Weighted multivariable logistic regression 
models adjusted for age, race/ethnicity, sex, and poverty income ratio (PIR), were used to 
determine the association of blood manganese levels and myocardial infarction, stroke, and renal 
dysfunction accounting for the complex sample survey design.  
Results: The mean and standard errors (SEs) of blood manganese levels for myocardial 
infarction were [10.2 (0.4) µg/L], stroke [9.6 (0.2) µg/L], and renal dysfunction [9.4 (0.1) µg/L] 
for the combined six years. In the adjusted models, the odds of myocardial infarction [odds ratio 
(OR) 1.20 (95% CI: 0.76-1.90)] were highest in the highest quartile (Q4: ≥11.3 µg/L) compared 
to the lower quartile (Q1: ≤7.36 µg/L). There was a non-signicant 17% increased odds of stroke 
1.17 (95% CI: 0.72-1.92) comparing the highest quartile (Q4) to the lowest quartile (Q1). There 
was a non-significant decreased odds of renal dysfunction 0.80 (95% CI: 0.62-1.05) in the 
highest quartile (Q4) compared to the lowest quartile (Q1).   
Conclusion: The increasing odds for stroke and myocardial infarction based on the manganese 
quartiles, suggests that increased blood manganese levels may play an important role in the 
disease process.  
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CHAPTER 2 
INTRODUCTION 
 
Metals are abundant in the environment and their presence can be measured from many body 
compartments like whole blood, serum, plasma, urine, hair, and toenails for epidemiological 
studies.1 Most of the metals are essential but they can also give rise to adverse effects if their 
levels increase in the body. If they accumulate for an extended period they can be toxic to 
humans particularly in the young and the elderly.2-5  One of those essential elements is 
manganese (Mn), which the human body is introduced via food and water consumption.6 
Additionally, Mn is involved in many cellular functions like synthesis and activation of enzymes. 
After it is absorbed from the gastrointestinal tract, it is transported to mitochondria rich organs 
like the liver, pancreas, and the pituitary gland.7,8 Since it is important for synthesis and 
activation of enzymes (e.g., hyrdrolases, isomerases, ligases, lyases, oxidoreductases, and 
transferases), it plays a role in protection of oxidative stress and also helps in the formation of 
connective tissue and bone.7 The normal range of Mn ranges between 4-15 µg/L in blood. With 
excess exposure it has been known to cause manganism that is manifested in neurological 
symptoms that are similar to Parkinson’s disease.9 In the general population, the primary 
pathway of exposure is through the consumption of food and water,9 but populations can have 
environmental exposure if they reside closer to industries with Mn emissions.9 Workers from the 
mining and welding industries have a greater risk from over exposure to Mn.10,11  
 A genetic animal study12 found that a certain amount of Mn exposure could reduce the 
inflammatory response to stressful environments in rats. Mn protects cells from antioxidant 
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processes as a cofactor for the metalloenzyme superoxide dismutase.13 An animal study14 by 
Malecki et al. (1996) demonstrated that Mn deficiency leads to reduced Mn superoxide 
dismutase (MnSOD) activity that caused in vivo oxidative stress to heart mitochondria in rats. 
Thus, a subclinical Mn deficiency could increase oxidative stress. However, there is limited and 
inconsistent information of the role of Mn from molecular biology and population-based studies. 
Since, Mn deficiency and excess levels are both associated with adverse neurologic and 
metabolic outcomes.15,16    
 Previous studies have investigated the association of Mn and myocardial infarction 
(MI),17-21 stroke,19,22 and renal dysfunction.19 However, some of those studies used serum 
Mn18,20,21 levels and one study used plasma Mn22 levels as the exposure. A case-control study17 
found blood Mn levels were lower among those with MI and a study20 by Manthey et al. (1981) 
found that plasma Mn levels were higher among those diagnosed with an MI. Two studies 
investigated the association of Mn with stroke—one population based cross-sectional study used 
blood Mn19 and the other case-control study22 used plasma Mn as the biomarker for exposure. 
However, the studies that found an association or no positive association for these chronic 
diseases had problems with adequate sample sizes17,18,20 or differing exposure biomarker.20,22 
Oxidative stress and inflammation are the main pathophysiological processes underlying chronic 
diseases.  
Prior studies have not provided sufficient evidence to support associations of blood Mn 
levels and the three chronic diseases. Therefore, we hypothesize that blood Mn levels could be 
related to the prevalence of chronic diseases. The purpose of this cross-sectional study is to 
describe the association of blood Mn levels with three chronic diseases (MI, stroke, and renal 
dysfunction).  
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METHODS 
Data source 
The United States National Health and Nutrition Examination Survey (NHANES) is a complex, 
stratified, multistage, probability cluster sampling design to select a representative sample of the 
US civilian non-institutionalized population. Our analyses were limited to survey data cycles 
from 2011-2012, 2013-2014, and 2015-2016 for participants 20 years and older (n=16245). The 
overall response rate for the survey cycles for 2011-2012, 2013-2014, and 2015-2016 were 
69.5%, 68.5%, and 58.7%, respectively. The NHANES is a unique survey which collects 
participant information from questionnaires administered at home and standardized health 
examinations conducted at specialized mobile examination centers (MECs).  
The NHANES used a four-stage sample design for 2011-2016.  The first stage is sampled 
from a frame of all US counties known as the primary sampling units (PSUs). The PSUs were 
mostly counties but in a few instances, adjacent counties were combined to keep the PSUs above 
a certain minimum size. The PSUs for NHANES are chosen based on the probabilities 
proportional to a measure of size (PPS) which corresponds to the population count of the PSU.  
The second stage consists of the selection of area segments that comprise of census 
blocks or a combination of blocks. The third stage consisted of the selection of dwelling units 
(DUs). From the selected PSU, following the selection of the segments, a list of all DUs from the 
sampled segments is prepared. A subsample of these DUs is carried out to in order to produce a 
national probability of sampled households.  
The fourth stage consists of the sampling of the persons from the occupied DUs or 
households. From the list of all the eligible members of the household, a subsample of 
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individuals are selected based on age, sex, race, and Hispanic origin.23  Informed consent was 
obtained from all participants for the personal interview and medical examination participants. 
We further excluded women who were pregnant at the time of the survey because of the effect of 
pregnancy on blood Mn levels.  
Study variables 
In NHANES, a standardized questionnaire is used to collect demographic information and 
medical history. We defined cardiovascular disease as a self-reported history of MI and stroke. 
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation,24 and renal dysfunction was defined as 
albumin-to-creatinine ratio ≥30 mg/g or eGFR ≤60 ml/min/1.73 m2 using serum creatinine 
levels. The other demographic covariates that are used were age group (20-44, 45-54, 55-64, 
≥65), sex, race, and, poverty income ratio [(PIR), the ratio of self-reported family income to the 
family’s appropriate threshold value based on federal poverty level, grouped in quartiles].  
Mn levels were measured with whole blood specimens that were frozen (–30oC), stored, and 
shipped for analysis to the Division of Laboratory Sciences, National Center for Environmental 
Health (CDC).  Whole blood Mn levels were measured in participants 20 years and older, using 
inductively coupled plasma mass spectrometry (ICP-MS).  
Statistical analysis 
Descriptive results are presented based on MI, stroke, and renal dysfunction. Weighted mean and 
standard errors were calculated for continuous variables (age and PIR), while weighted 
frequencies with standard errors are reported for categorical variables. We used weighted 
multivariable logistic regression to examine the association of blood Mn levels and MI, stroke, 
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and renal dysfunction adjusting for demographic variables like age, race, sex, and PIR and 
reported odds ratios (ORs) and 95% confidence intervals (CIs). We further investigated 
differences in blood Mn levels by PIR. The analyses for the combined years were re-weighted to 
adjust for the complex sample survey design using SURVEYFREQ, SURVEYMEANS, and 
SURVEYLOGISTIC procedures. All comparisons were considered statistically significant with 
a p < 0.05. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) using 
survey procedures.  
 
RESULTS 
This study included 16,229 adults aged 20 years and older from 2011-2016 NHANES surveys, 
we excluded women who identified as pregnant (n=136) at the time of the survey.  The 
combined weighted prevalence of MI, stroke, and renal dysfunction was 3.3%, 2.9%, and 9.6%, 
respectively (data not shown). Demographic characteristics, general health conditions, health-
related behaviors, and blood Mn concentration (µg/L) by MI, stroke, and renal dysfunction are 
presented in Table 1. The mean (SE) for blood Mn levels for MI was 10.2 µg/L, stroke (9.8 
µg/L), and renal dysfunction (9.4 µg/L). The estimated blood Mn levels were lowest among 
those with renal dysfunction compared to those without renal dysfunction (9.7 µg/L). The 
distribution of blood Mn concentrations was 7.36, 9.07, and 11.29 for the 25th, 50th, and 75th 
percentiles, respectively (data not shown). In comparison to age, the prevalence of self-reported 
MI (10.3%) was highest among adults 65 years and olde, self-reported stroke (8.6%), renal 
dysfunction (33.8%) compared to adults younger than 65 years. Prevalence of self-reported MI 
(3.8%) and renal dysfunction (11.5%) was highest among Whites compared to persons Blacks, 
Hispanic, and other races; while, Blacks had the highest prevalence of stroke (3.7%) compared to 
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Whites, Hispanic, and other races . Based on poverty income ratio (PIR), participants in the low 
income level (1.3 to 3.49) had the highest prevalence of self-reported MI (4.5%), stroke (4.3%) 
compared to middle- and high-income level groups; while, renal dysfunction (10.8%) was the 
highest among middle income level compared to the low- and high-income levels . When 
compared to smoking status, the prevalence of self-reported MI was highest among former 
smokers (5.4%) compared to current smokers (4.5%) and never smokers (2.0%), while the 
prevalence of self-reported stroke was highest among former smokers (4.3%), and the prevalence 
of renal dysfunction was highest among former smokers (15.1%) followed by never smokers 
(8.7%), and current smokers (5.0%). 
 We performed unadjusted and adjusted weighted multivariable logistic regression models 
to determine the association between blood Mn, MI, stroke, and renal dysfunction with quartile 1 
(≤7.36 µg/L) as the reference category (Table 2). In the unadjusted models, the odds of renal 
dysfunction reduced for blood Mn quartiles Q2 to Q4 with a 36% reduction for Q4 (OR: 0.64, 
95% CI: 0.52-0.77) compared to participants in blood Mn Q1 quartile. There were no significant 
associations in the unadjusted models for MI Q2 (OR: 0.74, 95% CI: 0.53-1.03) and stroke Q3 
(OR: 0.88, 95% CI: 0.54-1.44) compared to participants in blood Mn Q1. In the adjusted models 
controlling for age group, sex, race, and PIR there was no significant association between blood 
Mn Q4 (OR: 0.80, 95% CI: 0.62-1.05) and renal dysfunction compared to participants in Q1 
blood Mn quartile. There were also no significant association for blood Mn Q2 (OR: 1.09, 95% 
CI: 0.66-1.79) for stroke and Q2 (OR: 0.88, 95% CI: 0.54-1.44) for MI compared to Q1 blood 
Mn quartile. We further investigated for effect measure modification of blood Mn and PIR in all 
the models; however, the interaction was not statistically significant.   
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DISCUSSION 
In a nationally representative study from the US this study showed that blood Mn levels were not 
associated with self-reported MI, stroke, and renal dysfunction after adjusting for 
sociodemographic covariates. Blood Mn were lower among males compared to females and 
Black males had lower blood Mn levels compared to White, Hispanic, and other races. We did 
not find a positive association for blood Mn levels and MI, stroke, and renal dysfunction. This 
suggests that blood Mn might not be involved in the pathophysiological processes for MI, stroke, 
and renal dysfunction.  
 Blood Mn has been used as a biomarker in epidemiological studies, it has been used as an 
exposure biomarker for Mn inhalation.13 Mn is found richly in tissues rich with mitochondria, at 
present there is no reliable biomarker than can measure Mn accumulation accurately, due to a 
discrepancy in the half-life of Mn in the tissues and blood.19  However, Mn levels in whole blood 
are considered more reliable than plasma.13 Blood Mn levels were lower in participants with 
renal dysfunction but not in participants with MI and stroke. Previous studies have explored the 
relationship of Mn and MI,17-21 stroke,19,22 and renal dysfunction, two of those studies for MI 
used blood Mn levels as the biomarker, while the other three studies used plasma Mn levels. Of 
the studies with blood Mn as the biomarker, one case-control study17 found that lower blood Mn 
levels were associated with MI; however, the findings are questionable given the lack of 
adequate controls in the study. The other population-based cross-sectional study19 from Korea 
found that there was no association between blood Mn and MI; although, they had a 45.0% non-
significant lower odds in the highest blood Mn quartile (15.6 µg/L) compared to Q1 (≤10.5 
µg/L). There were two studies for stroke and one cross-sectional study19 used blood Mn as a 
biomarker that did not find an association with blood Mn levels; however, we found a similar 
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non-significant 20% increase of the odds of stroke in the highest quartile (11.3 µg/L). The other 
case-control study22 from China used plasma Mn levels and found that the highest quartile 
(>41.8 µg/L) had a 3-fold increased odds of stroke compared to the first quartile (<17.7 µg/L) of 
plasma Mn levels. There was one cross-sectional study19 by Koh et al. (2014) on blood Mn levels 
and renal dysfunction that found blood Mn levels between (10.6 to 12.7 µg/L) had a 49% lower 
odds of renal dysfunction, while we found a 20% non-significant lower odds in blood Mn levels 
(>11.3 µg/L) . Although we did not find an association in the adjusted model for renal 
dysfunction, our adjusted model controlled for sociodemographic and socioeconomic factors, 
while the Koh et al. (2014) study19 adjusted for body mass index (BMI), diabetes, and 
hypertension in addition to age and sex.  
 This is the first population-based study in the US using a nationally representative 
general US population that examined the association of blood Mn and MI, stroke, and renal 
dysfunction. Most studies have found environmental Mn toxicity to be associated with adverse 
outcomes compared to dietary intake and metabolism.15,25  Mn toxicity occurs due to chronic 
inhalation with high concentration of Mn particles in the air.25,26 This toxicity has been mainly 
observed in miners, ferroalloy workers, and battery manufacturing workers.15,26 Since, oxidative 
stress plays an important role in atherosclerosis and manganese superoxide dismutase (MnSOD) 
is transcriptionally transported to the mitochondria, several studies27,28 have shown that MnSOD 
polymorphisms induce oxidative stress and could lead to severe cardiac outcomes. In the US, Mn 
exposure can occur among miners, ferroalloy workers, and residents that live in close proximity 
to the mining industries. Mn toxicity has been known to induce tremors, rigidity, postural 
instability that closely resemble idiopathic Parkinson’s disease.29 some patients exhibit 
neuropsychological symptoms like apathy and psychosis as it targets the dopaminergic system of 
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the brain that mimics Parkinson’s disease.29 Although, we did not find an association with renal 
dysfunction, one study19 in Korea did find a statistically significant association with lower blood 
Mn levels. Nevertheless, this association needs to be examined further to verify this hypothesis.  
 This study had some important limitations. First, we used a cross-sectional study design, 
and therefore, we cannot make any temporal associations with the simultaneous assessment of or 
outcomes and exposure. Therefore, we could not assess the changes in blood Mn levels over time 
to establish a causal association. Some of the outcomes were based on self-reports by the 
participants, thus we could underestimate or overestimate our findings. Some of our adjusted 
models could be affected by unmeasured variables such as serum iron or albumin levels that are 
important proteins in Mn-binding in the blood. Although, we looked for correlations with other 
heavy metals in blood like lead, selenium, cadmium, and mercury, we were unable to adjust for 
metals that have the same valence states as Mn like copper and calcium. There is a possibility 
that some of the participants with chronic diseases may not have had Mn readings that could 
affect the lack of association in our study. Lastly, we were not able to classify participants based 
on their occupation due to a large percentage of missing observations. Despite these limitations, 
we used a nationally representative US general population using standard analytical and quality 
control procedures of NHANES.  
 In conclusion, we found blood Mn is not associated with MI, stroke, and renal 
dysfunction. However, further prospective cohort studies are needed to determine protective or 
adverse effects of Mn for renal dysfunction.  
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TABLES 
 
Table 1. Participant characteristics of blood manganese (Mn) (µg/L) according to self-reported 
myocardial infarction, stroke, and renal dysfunction status among US adults aged 20 years and 
older—NHANES, 2011-2016 
 Myocardial infarction Stroke Renal dysfunction 
Yes No Yes No Yes No 
Characteristics n %  n % n %  n %  n %  n %  
Age group, y             
   20-44 40 0.5 6886 99.5 45 0.6 6884 99.4 56 0.8 6874 99.2 
   45-54 53 1.4 2723 98.6 64 1.7 2711 98.3 126 5.0 2651 95.0 
   55-64 155 5.1 2649 94.8 143 3.6 2661 96.4 304 10.5 2501 89.5 
   ≥65 407 10.3 3316 89.7 356 8.6 3368 91.4 1310 33.8 2423 66.2 
Sex, (male) 412 4.1 7492 95.9 294 2.7 7613 97.3 871 8.3 7042 91.8 
Race             
   White  338 3.8 5746 96.2 274 2.9 5813 97.1 972 11.5 5120 88.5 
   Black 127 2.7 3552 97.3 171 3.7 3511 96.2 381 8.0 3301 92.0 
   Hispanic  132 1.9 3809 98.0 108 1.8 3829 98.2 294 4.3 3650 95.7 
   Other  58 3.0 2467 97.0 55 3.0 2471 97.0 149 5.5 2378 94.5 
PIR             
   <1.3 273 4.5 4805 95.5 240 4.3 4840 95.6 565 9.5 4519 90.5 
   1.3-3.49 207 3.7 5123 96.3 226 3.5 5104 96.5 660 10.8 4674 89.2 
   ≥3.5 115 2.2 4275 97.8 90 1.5 4300 98.5 412 8.5 3980 91.5 
BMI, Kg/m2             
   Normal 137 2.3 4384 97.7 144 2.5 4379 97.5 361 7.4 4166 92.6 
   Overweight  196 3.0 4941 97.0 180 2.5 4960 97.5 611 10.2 4530 89.8 
   Obsese  287 4.1 5802 95.9 239 3.1 5847 96.9 759 10.5 5335 89.5 
Cigarette 
smoker 
            
   Current  159 4.5 3062 95.4 150 3.6 3072 96.4 213 5.0 3010 95.0 
   Former 261 5.4 3482 94.6 213 4.3 3530 95.7 687 15.1 3063 84.9 
   Never  234 2.0 9013 97.9 245 2.0 9004 98.0 894 8.7 8359 91.3 
Diabetes 239 10.8 1944 89.2 202 8.4 1984 91.6 574 24.7 1613 75.3 
Hypertension 509 7.5 5461 92.6 458 6.5 5513 93.5 1314 19.9 4664 80.1 
Blood Mn 
(µg/L), mean 
(SE) 
 
9.6 
 
0.2 
 
9.7 
 
0.1 
 
9.6 
 
0.2 
 
9.7 
 
0.1 
 
9.2 
 
0.1 
 
9.7 
 
0.1 
Abbreviations: Body mass index (BMI); normal = 18.5-24.9, overweight = 25.0-29.9, obese = 30.0 and above. PIR, 
(poverty income ratio); low <1.3, middle = 1.3 to 3.49, high ≥3.5. 
Note: Renal dysfunction was calculated using CKD-EPI equation eGFR = 141 x min(SCr/κ, 1)α x max(SCr /κ, 1)-
1.209 x 0.993age x 1.018 [if female] x 1.159 [if Black]. eGFR < 65 is defined renal dysfunction. 
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Table 2. Estimates of unadjusted and adjusted logistic regression analysis of blood Mn (mcg/dL) 
and myocardial infarction, stroke, and renal dysfunction among adults 20 years and older—
NHANES, 2011-2016.  
 Myocardial infarction Stroke Renal dysfunction 
 OR (95% CI) OR (95% CI) OR (95% CI) 
Characteristics Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted 
Mn quartile 
(µg/L) 
      
   Q1 (≤7.36) Ref  Ref  Ref  Ref  Ref Ref  
   Q2 (7.37-9.06) 0.74  
(0.53-1.03) 
0.88  
(0.60-1.27) 
0.98  
(0.62-1.56) 
1.10  
(0.72-1.72) 
0.77  
(0.62-0.95) 
0.87  
(0.67-1.12) 
   Q3 (9.07-
11.29) 
0.84  
(0.55-1.28) 
1.11  
(0.68-1.81) 
0.88  
(0.54-1.44) 
1.09  
(0.66-1.79) 
0.74  
(0.61-0.91) 
0.97  
(0.75-1.24) 
   Q4 (≥11.3) 0.94  
(0.66-1.34) 
1.20  
(0.76-1.90) 
0.91  
(0.57-1.47) 
1.17  
(0.72-1.92) 
0.64  
(0.52-0.77) 
0.80  
(0.62-1.05) 
Age group, 
years 
      
   20-44 Ref  Ref  Ref  Ref  Ref  Ref  
   45-54 2.80  
(1.85-4.22) 
3.74  
(2.17-6.46) 
2.90  
(1.86-4.53) 
4.45  
(2.41-8.19) 
6.52  
(4.46-9.52) 
6.31  
(3.98-9.99) 
   55-64 10.86  
(7.32-16.12) 
13.45  
(7.5-24.1) 
6.14  
(3.97-9.50) 
7.84  
(4.2-14.7) 
14.65  
(9.7-22.2) 
15.8  
(8.9-28.0) 
   ≥65 23.1 
(16.29-32.7) 
27.6  
(16.8-45.3) 
15.6  
(10.9-22.5) 
20.5  
(12.4-33.9) 
63.9  
(45.7-90.3) 
62.97  
(41.0-96.6) 
Sex        
   Female  Ref Ref Ref Ref Ref Ref 
   Male   1.64 
 (1.34-2.01) 
2.03  
(1.50-2.73) 
0.87 
 (0.70-1.10) 
1.04  
(0.79-1.36) 
0.31  
(0.02-4.25) 
0.83  
(0.67-1.04) 
Race        
   White  Ref Ref Ref Ref Ref Ref 
   Black 0.70 
 (0.56-0.88) 
0.95  
(0.65-1.37) 
1.31  
(1.08-1.57) 
1.37 
 (1.08-1.75) 
0.67  
(0.58-0.76) 
0.96  
(0.79-1.17) 
   Hispanic  0.51  
(0.39-0.66) 
0.71  
(0.54-0.92) 
0.62  
(0.49-0.78) 
0.8  
(0.56-1.14) 
0.35 
 (0.29-0.42) 
0.61  
(0.48-0.81) 
   Other  0.79  
(0.50-1.25) 
0.75  
(0.45-1.27) 
1.06  
(0.69-1.62) 
1.10 (0.62-
1.97) 
0.45 
 (0.35-0.57) 
0.62  
(0.47-0.81) 
PIR       
   <1.3 Ref Ref Ref Ref Ref Ref 
   1.3-3.49 2.07  
(1.50-2.86) 
3.00  
(1.95-4.60) 
3.01  
(2.16-4.19) 
4.08  
(2.69-6.19) 
1.13  
(0.92-1.39) 
1.55  
(1.26-1.90) 
   ≥3.5 1.67  
(1.14-2.45) 
1.86  
(1.09-3.17) 
2.41  
(1.80-3.23) 
2.39  
(1.66-3.42) 
1.29  
(1.14-1.48) 
1.22  
(0.98-1.53) 
Abbreviations: Odds ratio (OR); confidence interval (CI). PIR [poverty income ratio; low (<1.3), middle 
(1.3 to 3.49), high (≥3.5)].  
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FIGURES 
Figure 1. Estimated blood Mn levels (µg/L) according to sex and race/ethnicity among 
adults 20 years and older—NHANES, 2011-2016 
 
Figure 2. Estimated blood Mn levels (µg/L) by age-group (years) among adults aged 20 
years and older—NHANES, 2011-2016 
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ABSTRACT  
Introduction: The objective of this study was to estimate the influence of the Affordable Care 
Act (ACA) Medicaid Expansion on current smoking and quit attempts in expanded and non-
expanded states.  
Methods: We analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS) 
between 2003 through 2015 to evaluate changes in current smoking and quit attempts using 
multivariable logistic regression and generalized estimating equations (GEE), adjusting for 
socioeconomic factors. Time periods evaluated were: 2003-2009 (pre-expansion) and 2011-2015 
(post-expansion), and in supplemental analysis, also 2011- 2017.  
Results: Overall, smoking prevalence among adults in expanded and non-expanded states were 
16% and 17% (p < 0.001), respectively, and quit attempt prevalence for expanded and non-
expanded states were 56% and 57% (p = 0.05), respectively. In adjusted models comparing post- 
versus pre- expansion periods, current smoking declined by 6% in both expanded (RR: 0.94, 
95% CI: 0.93-0.94) and non-expanded (RR: 0.94, 95% CI: 0.94-0.95) states. Quit attempts 
increased by 4% (RR: 1.04, 95% CI: 1.04-1.05) in expanded states, and by 3% (RR: 1.03, 95% 
CI: 1.02-1.03) in non-expanded states. States that imposed barriers to utilization of smoking 
cessation services e.g. prior authorization, saw only a 3% increase in quit attempts regardless of 
expansion status, while expanded states that did not impose barriers experienced a 6% (RR: 1.06, 
95% CI: 1.05-1.06) increase in quit attempts.  
Conclusion: Reducing administrative barriers to smoking cessation programs may enhance 
further declines in smoking rates among US adults.   
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CHAPTER 3 
INTRODUCTION 
Cigarette smoking is the leading cause of preventable morbidity and mortality in the United 
States and accounts for approximately 480,000 deaths each year.1,2  There have been significant 
declines in cigarette smoking, from 42% in 1965 to 15% in 2015.3 However, current smoking 
remains disproportionately higher among low-income (30%) and uninsured (28%) individuals.4  
The Affordable Care Act (ACA), introduced in 2010, addressed provisions for healthcare 
coverage denial due to pre-existing conditions, provided tax-credits and subsidies to purchase 
health insurance and access to free preventive care, and expanded insurance coverage to include 
non-disabled single childless adults.5-7  As part of the ACA provision, childless adults could be 
Medicaid eligible at or below 133 percent federal poverty level (FPL).7  A total of 30 US states 
including the District of Columbia had expanded Medicaid as part of the ACA by December 31, 
2015, however in March 2010, six states and jurisdictions—California, Connecticut, the District 
of Columbia, Minnesota, New Jersey, and Washington— enacted Medicaid expansion among 
low-income groups due to the provisions in the ACA.8  
Prior to the ACA, low-income adults without Medicaid coverage had few available 
choices for accessing smoking cessation services and states had flexibility in types of smoking 
cessation services offered through Medicaid.9 However, following the implementation of the 
ACA, state Medicaid programs were required to cover smoking cessation services among newly 
eligible adults,10 leading to expanded coverage of evidence-based smoking cessation treatments. 
Previous studies have evaluated the impact of ACA expansion on quit attempts and current 
smoking, however prior studies have only evaluated annual trends, focused on a single or few 
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US states, or did not account for baseline differences in states Medicaid expansion status.11-14 
The purpose of this study is to evaluate the impact of the ACA expansion on current smoking 
and quit attempts among expanded and non-expanded US states, to evaluate the impact among 
low-income individuals, and to account for state-level barriers to smoking cessation services. 
    
METHODS 
Data source: Data were obtained from the Behavioral Risk Factor Surveillance System (BRFSS) 
for adults 18 years and older surveyed between 2003 and 2017.15 The BRFSS collects nationally 
representative data annually on randomly selected land-line and cell-phone telephone numbers 
on over 400,000 adults in all 50 states, including three U.S. territories and the District of 
Columbia.16 The annual telephone survey obtains information on health related risk behaviors, 
chronic health conditions and use of preventive services. The BRFSS median response rate over 
the study period ranged from 53% in 2003 to 47% in 2015.15 In the current analyses, data on 
socio-demographics, current smoking and quit attempts were obtained from the BRFSS, and data 
on Medicaid expansion status and year of expansion by state was obtained from the Kaiser 
Family Foundation State Health Facts.17  
Study variables: Outcome variables of interest were current smoking and quit-attempts in the 
past year among smokers. Current smokers were defined as participants who indicated that they 
currently smoked every day or some days, or that they had smoked a cigarette within the past 
month. Quit-attempts among smokers was defined as having a quit-attempt in the preceding 12 
months for one day or longer. Current smoking was defined using the ‘computed smoking status’ 
variable, while quit-attempts was defined using the variable ‘_STOPSMK2’ in the past year 
among current smokers.  Sociodemographic characteristics, including age, sex, race/ethnicity, 
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education, employment status, and annual household income were obtained, and data on 
availability of regular healthcare providers and health care coverage were included to examine 
access to healthcare. Age variable was classified in three groups; 18 – 49, 50 – 79, and 80+ years 
of age; annual household income variable was categorized into four groups- <$10,000, $10,000-
<$20,000, $20,000-<$50,000, and ≥$50,000; race was identified using the five level 
race/ethnicity variable and classified into White, Black, Hispanic, and Other categories; 
education was categorized into <high school, high school graduate, and some college or higher. 
Healthcare coverage was ascertained as having any kind of coverage, including health insurance, 
prepaid plans such as Health Maintenance Organizations (HMOs), or government plans like 
Medicare, or Indian Health Service. To evaluate the impact of state-level barriers to utilization of 
smoking cessation services, data on two state-level barrier variables – prior authorization before 
smoking cessation treatment and copayments- were obtained from the American Lung 
Association for 2010, dichotomized as yes/no.18  
Study Periods: The two study periods, pre-expansion (2003–2009) and post-expansion (2011–
2015), were defined based on states’ Medicaid expansion status during the study period.  Five 
states and the District of Columbia expanded eligibility as early as 2010 by taking advantage of 
provisions in the ACA and Medicaid waivers,7,8 therefore we considered the year 2010 as the 
washout period. By 2015, the following states had expanded Medicaid as part of the ACA; 
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Indiana, Iowa, 
Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire, 
New Jersey, New Mexico, New York, North Dakota, Ohio, Oregon, Pennsylvania, Rhode Island, 
Vermont, Washington, West Virginia, and District of Columbia. To evaluate more recent trends 
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in current smoking and smoking cessation, we also examined BRFSS data from 2011 to 2017; 
comparing 2011-2013 and 2015-2017 time periods. 
Statistical analysis: Weighted analyses for descriptive variables by expansion status using chi-
square tests, were evaluated for current smoking and quit attempts by socio-demographic 
variables and expansion status. We assessed annual trends in current smoking and quit attempts 
by expansion status, and utilized multivariable adjusted logistic regression and generalized 
estimating equations (GEE) to assess current smoking and quit attempts in the past year in non-
expanded versus expanded states for each time period. Due to the high prevalence of current 
smoking and quit attempts in the past year, we interpret estimates from GEE models as relative 
risks (RRs) instead of odds ratios (ORs).19 To examine the secular time trends in the prevalence 
of current smoking and quit-attempt status among adults in the two time periods, we assessed for 
linear and quadratic changes adjusting for socio-demographic and socio-economic predictors in 
pre-expansion (2003–2009) and post-expansion (2011–2015) periods. Similar analyses were 
conducted for 2011-2013 versus 2015-2017 (supplemental tables). We also assessed for 
interactions between expansion status and time periods in prevalence of current smoking and 
quit-attempts. Furthermore, we evaluated whether the association between expansion and 
smoking cessation varied by state-level barriers such as prior authorization and co-payments for 
smoking cessation treatment. All analyses were carried out using SAS version 9.4 (SAS Institute, 
Inc., Cary, NC; USA) accounting for the complex sample survey design; statistical significance 
levels were determined based on p-values < 0.05. 
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RESULTS 
By December 31, 2015, 30 states and DC had implemented Medicaid expansion, while 21 states 
had not implemented the policy. A total of 5,311,872 participants were included in this analysis, 
2,289,033 (43%) were in non-expanded states and 3,022,839 (57%) were in expanded states 
(Table 1). Table 1 shows the baseline characteristics of the study participants overall and by 
Medicaid expansion status. Participants in expanded vs. non-expanded states were less likely to 
be Black (7% vs. 10%), more likely to be Hispanic (7% vs. 5%), have at least some college 
education (64% vs. 60%), have an average annual household income of >$50,000 (47% vs. 
41%), more likely to have health insurance coverage (91% vs. 88%) and at least one regular 
healthcare provider (86% vs. 84%).  
Overall, 16% of participants residing in expanded states were current smokers, compared 
with 17% of participants in non-expanded states (Table 2; p<0.001). The prevalence of current 
smoking in the expanded states declined from 23% to 14%, and in the non-expanded states 
reduced from 22% to 15% between 2003 and 2015 (Figure 1). For quit attempts, prevalence in 
expanded states increased from 53% to 57%, and in the non-expanded states it increased from 
51% to 58% (Figure 2). Current smoking was lower in expanded vs. non-expanded states, 
especially among participants aged 18-34 (22% vs. 23%), those without health insurance 
coverage (31% vs. 33%), those with an annual household income less than $10,000 (31% vs. 
32%) and those who were unemployed (30% vs. 34%). The prevalence of current smoking in the 
expanded states declined from 23% to 14%, and in the non-expanded states reduced from 22% to 
15% between 2003 and 2015 (Figure 1). For quit attempts, prevalence in expanded states 
increased from 53% to 57%, and in the non-expanded states it increased from 51% to 58% 
(Figure 2). 
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In models adjusted for sex, race, income, education, and comparing non-expanded versus 
expanded states (Table 3), current smoking increased by 2% (RR: 1.02, 95% CI: 1.02-1.03) in 
the pre-expansion period (2003-2009), but no significant difference was found post-expansion 
(RR: 0.99, 95% CI: 0.99-1.00) . In addition, quit attempts declined by 2% pre-expansion (RR: 
0.98, 95% CI: 0.98-0.99), and increased by 1% (RR: 1.01, 95% CI: 1.01-1.02) post-expansion. In 
Table 4, comparing post- versus pre- expansion periods, current smoking declined by 6% in both 
expanded (RR: 0.94, 95% CI: 0.93-0.94) and non-expanded (RR: 0.94, 95% CI: 0.94-0.95) 
states. Quit attempts increased by 4% (RR: 1.04, 95% CI: 1.04-1.05) in expanded states post- 
versus pre- expansion, and by 3% (RR: 1.03, 95% CI: 1.02-1.03) in non-expanded states. When 
focused on low income individuals (annual household income <$20,000), there was no 
significant change in current smoking post versus pre- expansion in either expanded or non-
expanded sates, but there quit attempts increased by 5% (RR: 1.05, 95% CI: 1.05-1.06) in 
expanded states and by 4% (RR: 1.04, 95% CI: 1.04-1.05) in non-expanded states. More modest 
associations were observed in more recent BRFSS years (2011-2017); current smoking declined 
by 1% (RR: 0.99, 95% CI: 0.99-0.99) in 2011-2013, and increased by 1% (RR: 1.01, 95% CI: 
1.01-1.01) in 2015-2017. Quit attempts increased by 0.6% (RR: 1.006, 95% CI: 1.006-1.007) in 
2011-2013 period, and by 1% (RR: 1.01, 95% CI: 1.01-1.01) in 2015-2017. (Supplemental 
Tables 1-2).  
We further examined the association between Medicaid expansion and current smoking 
or quit attempts varied by state-level prior authorization and co-payment barriers. Among states 
that required prior authorization (Table 5), quit attempts increased by 3% (RR: 1.03, 95% CI: 
1.02-1.03) in the post versus pre-expansion period in both expanded and non-expanded states. 
However, among states that did not require prior authorization for smoking cessation, quit 
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attempts increased by 6% (RR: 1.06, 95% CI: 1.05-1.06) in expanded states, and increased by 
3% (RR: 1.03, 95% CI: 1.02-1.03) in non-expanded states. Among states that required co-
payments for smoking cessation services (Table 6), quit attempts increased by 3% (RR: 1.03, 
95% CI: 1.02-1.03) in expanded states, and by 2% (RR: 1.02, 95% CI: 1.02-1.03) in non-
expanded states. Among states that did not require copayments, quit attempts increased by 7% 
(RR: 1.07, 95% CI: 1.06-1.07) in expanded states, and by 3% in non-expanded states (RR: 1.03, 
95% CI: 1.03-1.04).   
 
        DISCUSSION  
In a large nationally representative study population of US adults, we examined the impact of the 
ACA expansion on current smoking and quit attempts in pre-expansion and post-expansion time 
periods. Overall, current smoking was 2% higher in the non-expanded versus expanded states in 
the pre-expansion period, but 1% lower post-expansion. However, in both expanded and non-
expanded states, there was a 6% decline in current smoking post- versus pre-expansion, and a 3-
4% increase in quit attempts. There was no significant change in current smoking among 
participants with an annual household income of ≤$20,000, but a 4-5% increase in quit attempts 
was observed in this group.  These results indicate that while non-expanded states had higher 
current smoking rates compared with expanded states pre-expansion, following implementation 
of the ACA Medicaid expansion policy, both expanded and non-expanded states experienced 
significant improvements in declining current smoking rates and higher quit attempts. However, 
expanded states that introduced barriers to accessing evidence based smoking cessation services, 
specifically prior authorization and co-payments, experienced very modest increases in quit 
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attempts post- versus pre- expansion, compared with states that did not institute such barriers, 
while such barriers made no difference in non-expanded states.  
Prior studies have analyzed the impact of Medicaid expansion on current smoking and 
quit attempt rates among US adults.2,20-24 The majority of those studies observed that following 
the implementation of Medicaid expansion as part of the Affordable Care Act, current smoking 
rates declined modestly,2,20,22,23 while quit attempts increased.2,21,24 Three studies utilized data 
from BRFSS to evaluate differences in current smoking post- versus pre-expansion and observed 
declines in current smoking ranging from 15%20 and 7%22 to 0.06%.23 Other studies have 
evaluated differences in prevalence of current smoking comparing trends over time,2,20,21,23 a 
study using the National Health Interview Survey (NHIS) observed that current smoking 
prevalence was 21% in 2005 and 15% in 2015,4 while a state-based study using the 
Massachusetts BRFSS observed that smoking prevalence decreased from 38% in 1999 to 28% in 
2008.20 Two studies using the BRFSS evaluated the effect of Medicaid expansion on quit 
attempts in the pre- versus post-expansion period, and observed that the odds of smoking 
cessation increased by 21% among US adults,22 while the other study observed that non-
expanded Medicaid enrollees had a 5% lower odds of quit attempts compared with enrollees.24 
Other studies have utilized data from specific states to evaluate expansion and quit attempts. For 
instance, a study of Medicaid enrollees in Alabama, Georgia, and Maine observed that the odds 
of quit attempts increased by 60% after the Medicaid expansion,25 while a study from northern 
California showed a 49% increase among Medicaid enrollees compared to those on commercial 
insurance.24 There are several potential reasons for the differences between these prior studies 
and our findings.  
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Compared with other studies,2,20,22,23 we observed a more modest 6% decline in current 
smoking among US adults in both expanded and non-expanded states comparing post- and pre-
expansion periods. That is, regardless of whether a state expanded Medicaid as part of the 
Affordable Care Act, current smoking declined by 6%, while quit attempts increased by 3-4%. 
Among low-income individuals, we did not observe a significant decline in current smoking, but 
did observe a 4-5% increase in quit attempts. This is similar to a 2% increase in quit attempts 
observed by a separate study12 using the BRFSS dataset. Our findings of current smoking 
prevalence of 26% in the non-expanded and 18% in the expanded states for participants of Other 
races (includes multiracial, American Indian/Alaska Native, and Asians) are also comparatively 
lower compared to a previous study4 using the NHIS that had a prevalence of 32% among 
American Indian/Alaska Natives. The lower rates could be due to the combination of racial 
groups i.e. American Indian/Alaska Natives and Asians with significantly different current 
smoking rates. Moreover, our results are based on an overall population average for 2003 to 
2015, while the NHIS study reported cross-sectional results for 2015.4  
The modest findings in our study may be explained by several possible reasons. First, in 
contrast to other studies, our analytic approach did not assume that states that expanded 
Medicaid as part of the Affordable Care Act were similar to states that did not expand at 
baseline. For instance, individuals in expanded states were younger, less likely to be Black, and 
had higher annual household incomes on average compared with individuals in states that did not 
expand. To account for these baseline differences, we estimated the risks of current smoking and 
smoking cessation in pre- versus post-expansion separately in expanded and non-expanded 
states, and statistically adjusted for these demographic differences. 
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Second, the modest declines in current smoking observed may be due to administrative and/or 
logistical barriers in accessing smoking cessation services that remained unaddressed or were 
newly implemented in some states after Medicaid expansion, a factor that was not directly 
considered in other studies. For instance, of the 31 states and jurisdictions that expanded 
Medicaid, only 19 states covered all the FDA-approved medications, while only 17 covered 
individual and 11 covered group counselling.26 Furthermore, some of the expanded states 
established administrative barriers such as co-payments and prior authorization for available 
treatments, therefore limiting access for cessation programs.27 In addition, prior to 2015, 48 
states covered some cessation treatments, but by June 2017, all of the 50 states and DC covered 
some form of tobacco cessation treatments.27 These may explain our observation of similar 
declines in current smoking and quit attempt rates between expanded and non-expanded states. 
That is, the added benefit of Medicaid expansion in improving access to smoking cessation 
services and hence reducing smoking rates may have been muted by accessibility barriers in 
expanded states, and provision of at least some smoking cessation services in non-expanded 
states. Based on our analyses, expanded states that had no barriers to smoking cessation 
treatments had a 7% increase in quit-attempts compared to a 3% increase among expanded states 
that had barriers in the post-expansion period. However, it is important to evaluate changes over 
time as benefits included in Medicaid coverage can change over time, for example North Dakota 
and Pennsylvania initially covered all cessation treatments, but no longer did so by June 2017.27  
Third, provision of smoking cessation services without other health policies such as 
indoor smoking bans, cigarette excise taxes and stricter age-limits, are likely to have limited the 
effectiveness of Medicaid expansion on smoking cessation. As of Jan 2018, only 28 states and 
D.C. have instituted a statewide smoking ban policy, and 47 states have increased cigarette taxes 
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with an average state tax of $1.69 per pack, ranging from $0.33 to $5.1.28 A 15% decline in 
current smoking was reported in Massachusetts,20 the first state to establish a Medicaid 
expansion program for low-income individuals. The program also provided fewer restrictions to 
participants, including lower administrative barriers to cessation services, and simultaneously 
implemented other smoking cessation policies such as indoor bans and higher excise taxes that 
likely contributed to its success.20 Treatment effectiveness may also vary- one study29 compared 
success rates in quitting gradually vs. abruptly found a significant quit rate (15% vs. 22%) at the 
end of six months in primary care clinics in England when included with behavioral support and 
nicotine replacement. A prior study has also reported that almost 85% of smokers quit smoking 
abruptly.30 We were unable to ascertain if our rates of quit attempts were based on counseling 
and nicotine replacement or just quit ‘cold-turkey’ as the BRFSS participants were not asked 
regarding cessation treatments.  
Fourth, Medicaid expansion was designed to increase insurance coverage for low-income 
individuals. Our study found no significant difference in current smoking in both the expanded 
and non-expanded states among low-income adults. This may be partly due to the increase in the 
Medicaid population over time; in 1997 low-income adults represented 8% of the US adult 
population, but by 2013 it had doubled almost to almost 17.31 In addition, many low-income 
individuals initiate smoking due to intense exposure to advertising, and personal psychosocial 
factors such as stress, financial burdens, and lack of social support.32-34 Medicaid expansion by 
itself is unlikely to address all these issues, and states may need to enhance tobacco cessation 
programs with other strategies including advertising restrictions especially for younger 
individuals, free or low-cost counseling and policies to further limit exposure to cigarettes. 
Current smoking was higher among 18-49-year olds in our study in non-expanded (21%) and 
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expanded (20%) states compared with other age-groups evaluated, highlighting the need for 
greater access to comprehensive smoking cessation services with limited financial and logistical 
barriers to utilization among younger adults. 
The strengths of our study are the use of a nationally representative non-institutionalized 
population of US adults across a wide range of racial, and socio-economic age groups. Our study 
estimates are reliable due to the large sample size across all sub-populations that provided 
adequate statistical power for the analysis. Also, we were able to assess study outcomes 
specifically among low-income individuals, since Medicaid expansion was designed to improve 
insurance coverage in this sub-population.  There are also certain limitations relevant to our 
study. First, we relied on self-reported data on smoking status and quit attempts, however, self-
reports of these variables have been validated previously.35 Second, measuring the impact of a 
general policy on individuals is vulnerable to ecological bias. Studies of low-income individuals 
comparing those enrolled in Medicaid as part of the Affordable Care Act with those who 
remained uninsured can provide better estimates of the direct association between expansion and 
smoking outcomes. We did not account for the time-varying nature of state-level barriers across 
the study period, but obtained data on barriers for the calendar year 2010. Lastly, the weighting 
methodology for BRFSS changed in 2010, thus estimates after 2011 were not comparable to 
previous years.36 To account for this, we examined the trends in the pre-expansion period (2003-
2009) and post-expansion periods (2011-2015) by categorizing expanded and non-expanded 
states, and examined the trends while considering calendar year 2010 as our wash-out period. 
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CONCLUSION 
In summary, our findings provide evidence that current smoking rates declined and quit attempts 
increased post-Medicaid expansion period; however, these trends were observed in both 
expanded and non-expanded states and were significantly influenced by state-level barriers to 
access smoking cessation services. Eliminating financial and logistical barriers to cessation 
services among Medicaid enrollees, and implementation of smoking related policies such as the 
indoor smoking ban and excise taxes may help to further reduce current smoking rates among 
US adults. 
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APPENDIX 
Table 1: Baseline characteristics of study population by Medicaid expansion status, BRFSS 2003-2015 (unweighted). 
                                  Expansion  
 
Characteristics 
Total 
(N = 5,311,872) 
Non-expanded  
States  (21) 
(N = 2,289,033) 
Expanded  
States (30) 
 (N = 3,022,839) 
p value 
Age     
18-34 796,657 (14.49) 345,041 (14.57) 451,616 (14.42) <.0001 
35-49 1,219,456 (21.20) 509,427 (20.57) 710,029 (21.70)  
50-64 1,642,264 (31.84) 701,298 (31.41) 940,966 (32.17)  
65-79 1,199,499 (24.25) 536,075 (25.0) 663,424 (23.68)  
≥ 80 403,594 (8.19) 178,504 (8.43) 225,090 (8.02)  
Sex      
Male 2,086,990 (39.98) 888,554 (39.46) 1,198,436 (40.36) <.0001 
Female 3,224,809 (60.02) 1,400,434 (60.54) 1,824,375 (59.64)  
Race      
White 4,176,702 (79.36) 1,814,675 (80.08) 2,362,027 (78.81) <0.001 
Black 429,021 (8.18) 225,859 (9.92) 203,162 (6.84)  
Other race 301,577 (5.87) 102,984 (4.56) 198,593 (6.88)  
Hispanic 336,421 (6.57) 118,687 (5.42) 217,734 (7.45)  
Education      
< High school 492,197 (8.78) 237,869 (9.80) 254328 (7.99) <0.001 
High school grad 1,576,718 (29.34) 492,197 (30.66) 710105 (28.33)  
Some college or higher 3,222,435 (61.87) 1,333,728 (59.53) 1888707 (63.66)  
Income level      
< $10,000 247,936 (5.38) 114,579 (5.73) 133,357 (5.11) <0.001 
$10,000 – < $20,000 637,669 (13.89) 299,939 (15.15) 337,730 (12.93)  
$20,000 – < $50,000 1,717,152 (36.54) 778,781 (38.59) 938,371 (34.97)  
≥ 50,000  1,947,866 (44.17) 762,843 (40.51) 1,185,023 (46.98)  
Employment      
Employed 2,296,526 (42.05) 962,264 (40.73) 1,334,262 (43.07) <0.001 
Self-employed 452,022 (8.39) 199,625 (8.63) 252,397 (8.21)  
Unemployed 257,218 (5.03)  102,243 (4.64) 154,975 (5.32)  
Student/Homemaker/Retired 1,073,783 (37.35) 843,350 (38.12) 1,073,783 (36.75)  
Unable to work 189,519 (7.16) 170,996 (7.86) 189,519 (6.62)  
Marital Status      
Married 2,878,492 (53.94) 1,273,187 (55.28) 1,605,305 (52.91) <0.001 
Divorced/Widowed/Separated 1,557,951 (29.61) 687,999 (30.28) 869,952 (29.10)  
Never married/Unmarried couple 847,402 (16.44) 317,997 (14.43) 529,405 (17.97)  
Healthcare Coverage *     
Yes 4,718,672 (89.74) 1,996,128 (88.09) 2,722,544 (91.00) <0.001 
No 576,588 (10.25) 285,477 (11.90) 291,111 (8.92)  
Healthcare Providers +     
At least one 4,523,661 (85.45) 1,925,100 (84.30) 2,598,561 (86.34) <0.001 
No 769,281 (14.54) 357,067 (15.70) 412,214 (13.65)  
 () Denotes column percentage. Sample sizes are unweighted; percentages are weighted to adjust for sampling and post-stratification. 
*Healthcare coverage is defined as having any kind of health care coverage, including health insurance, prepaid plans such as HMOs, or 
government plans such as Medicare. 
+Healthcare providers is defined as personal doctor or health care provider. 
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Table 2: Smoking Status by study period in the expanded and non-expanded states, BRFSS 2003 – 2015 (N 
= 5,311,799).  
 Smoking Status 
 Current Smoker* Quit Attempts 
Characteristics Non-expanded Expanded p value Non-expanded Expanded p value 
Overall  398,437 (16.6)  499,893 (15.90) <.0001 219,367 (56.61) 275,150 (56.38) 0.05 
Socio-Demographics       
Age       
18-34 79,937 (22.46) 100,966 (21.56) <.0001 51,018 (65.40) 63,752 (64.19) <.0001 
35-49 113,117 (20.99) 145,667 (19.56)  62,426 (57.16) 81,325 (57.44)  
50-64 138,497 (19.45) 172,103 (18.15)  74,064 (54.76) 92,100 (54.70)  
65-79 58,565 (10.81) 69,600 (10.46)  29,223 (50.78) 34,515 (50.38)  
≥ 80 6,264 (3.46) 8,242 (3.59)  2,636 (42.73) 3,458 (42.43)  
Sex        
Male 169,434 (18.32) 213,833 (17.27) <.0001 89,239 (53.96) 114,084 (54.54) <.0001 
Female 229,003 (15.58) 286,060 (14.98)  131,173 (58.60) 162,750 (57.84)  
Race        
White 307,000 (16.07) 384,156 (15.52) <.0001 161,934 (53.97) 204,189 (54.01) <.0001 
Black 42,342 (18.60) 39,288 (19.40)  28,883 (69.41) 26,314 (68.15)  
Other race   27,570 (26.12) 37,223 (18.16)  16,461 (60.68) 21,917 (59.81)  
Hispanic 17,545 (14.21) 33,257 (14.95)  10,985 (64.08) 21,133 (64.63)  
Healthcare Access       
Healthcare Coverage       
Yes 303,125 (14.50) 407,772 (14.46) <.0001 166,624 (56.20) 225,751 (56.33) <.0001 
 No 94,210 (32.70)  90,653 (30.53)  53,169 (57.82) 50,266 (56.44)  
Healthcare Providers        
At least one 300,058 (14.80) 391,389 (14.31) <.0001 169,097 (57.58) 220,773 (57.35) <.0001 
No 97,212 (26.66) 106,253 (25.26)  50,706 (53.66) 54,876 (52.73)  
Socio-economic Status       
Income level        
< $10,000 36,174 (32.02) 41,227 (31.16) <.0001 22,212 (62.81) 24,599 (60.78) <.0001 
$10,000 - < $20,000 76,965 (25.50) 86,079 (25.47)  45,485 (60.52) 50,089 (59.40)  
$20,000 - < $50,000 151,150 (18.48) 182,850 (18.68)  82,335 (55.77) 10,611 (55.92)  
≥ $50,000 88,676 (10.75) 133,184 (10.47)  46,089 (52.77) 71,597 (54.42)  
Education       
       <High school 64,218 (27.0) 67,379 (26.58) < .0001 37,016 (59.12) 37,967 (57.37) < .0001 
       High school grad 154,172 (21.12) 190,719 (21.51)  83,566 (55.53) 103,138 (54.98)  
       Some college or higher 179,344 (12.70) 240,561 (12.12)  99,466 (56.63) 135,099 (57.16)  
Employment        
Employed 180,242 (17.60) 230,795 (16.26) <.0001 97,836 (55.54) 126,946 (56.08) <.0001 
Self-Employed 32,272 (15.02) 38,167 (14.29)  16,554 (52.26) 19,985 (53.18)  
Unemployed 34,859 (33.66) 47,899 (30.40)  20,970 (61.51) 28,317 (60.07)  
Student/Homemaker/Retired 93,249 (10.60) 115,721 (10.42)  48,573 (52.84) 60,191 (52.46)  
Unable to work 56,559 (33.14) 65,265 (34.51)  35,837 (64.55) 40,344 (62.78)  
*Current smoker is defined as every day or someday smoker who smoked at least 100 cigarettes in their lifetime. 
Quit attempts is defined as stopped smoking for one day or longer because of trying to quit smoking. 
Expanded states include AK, AR, AZ, CA, CO, CT, DE, HI, IA, IL, IN, KY, MD, MA, MI, MN, NV, NH, NJ, NM, NY, ND, OH, OR, PA, 
RI, VT, WA, WV, and DC which expanded Medicaid under the ACA between 2010 and 2015 
Non-Expanded states did not expand Medicaid under the ACA till the end of 2015. 
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Table 3: Relative risks for current smoking and quit attempts by ACA expansion status and age-group, US BRFSS 
2003-2015 
 Current smokers (%) Quit Attempts (%) 
 
Year 
 
2003-2009* 
 
2011-2015† 
 
2003-2009† 
 
2011-2015† 
Overall US     
     Expanded  262,751 (17.22) 200,030 (16.07) 143,057 (55.31) 113,123 (56.86) 
     Non-expanded  205,078 (18.28)  160,235 (15.46) 110,105 (54.59) 91,410 (57.34) 
 RR = 1.02 (1.02-1.03) RR = 0.99 (0.99-1.00) RR = 0.98 (0.98-0.99) RR = 1.01 (1.01-1.02) 
18-49 years     
     Expanded  142,484 (21.61) 88,645 (19.79) 81,926 (58.52) 53,845 (61.14) 
     Non-expanded  108,863 (23.19)   70,683 (20.84) 61,681 (57.86) 43,527 (61.98) 
 RR = 1.02 (1.01-1.02) RR = 1.01 (1.01-1.02) RR = 0.99 (0.99-1.00) RR = 1.01 (1.01-1.02) 
50-79 years     
     Expanded  114,680 (15.45) 106,501 (14.68) 58,669 (52.42) 57,077 (53.83) 
     Non-expanded  92,283 (16.45) 85,935 (15.27) 46,729 (51.76) 46,245 (54.02) 
 RR = 1.02 (1.02-1.03) RR = 0.98 (0.98-0.99) RR = 0.98 (0.98-0.99) RR = 0.99 (0.99-1.00) 
>=80 years     
     Expanded  3,843 (3.87) 3,613 (3.46) 1,594 (41.74) 1,538 (42.85) 
     Non-expanded  2,766 (3.79) 2,895 (3.37) 1,128 (41.05) 1,241 (43.04) 
 RR = 0.96 (0.96-0.97) RR = 0.99 (0.99-1.00) RR = 0.96 (0.96-0.97) RR = 1.02 (1.02-1.03) 
Reference = Expanded; RR = relative risk. RRs for age categories have been adjusted for sex, race, annual household 
income, and educational status using Proc Genmod. Excluded 2010 data as the wash-out period. 
* Linear trend p = 0.13; quadratic trend p < 0.0001 
† Linear trend p < 0.0001 
 
 
Table 4. Relative Risks for Current Smokers and Quit Attempts by Expansion and Time Period, US BRFSS 2003-2015 
                                               Overall Low Income (≤$20,000) 
 Current Smoking* Quit Attempts* Current Smoking Quit Attempts* 
 RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
Expanded     
    Pre-expansion (2003-2009) Ref  Ref  Ref Ref 
    Post-expansion (2011-2015) 0.94 (0.93-0.94) 1.04 (1.04-1.05) 0.99 (0.99-1.00) 1.05 (1.05-1.06) 
Non-expanded     
    Pre-expansion (2003-2009) Ref  Ref  Ref Ref 
    Post-expansion (2011-2015) 0.94 (0.94-0.95) 1.03 (1.02-1.03) 0.99 (0.99-1.00) 1.04 (1.04-1.05) 
Note: Relative risks were adjusted for sex, race, annual household income, educational status including interaction terms for 
expansion status and time periods of pre-and post-expansion using Proc Genmod. Excluded 2010 data as the wash-out period. 
P-value for expand x period interaction: *<0.0001;  0.0019 
Annual household income ≤ $20,000 
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Table 5. Relative Risks for Quit Attempts by Expansion and Time Period by Prior Authorization, US BRFSS 
2003-2015 
 Quit Attempts Prior authorization 
 Overall Yes  No  
Expanded  RR (95% CI) RR (95% CI) RR (95% CI) 
    Pre-expansion (2003-
2009) 
Ref Ref Ref 
    Post-expansion (2011-
2015) 
1.04 (1.04 – 1.05) 1.03 (1.02 – 1.03)  1.06 (1.05 – 1.06) 
Non-expanded     
    Pre-expansion (2003-
2009) 
Ref Ref Ref 
    Post-expansion (2011-
2015)  
1.03 (1.02 – 1.03) 1.03 (1.02 – 1.03) 1.03 (1.02 – 1.03) 
Note: Relative risks were adjusted for sex, race, annual household income, educational status including interaction 
terms for expansion status and time periods of pre-and post-expansion using Proc Genmod. Excluded 2010 data as 
the wash-out period. 
Prior authorization required for smoking cessation among states include: AK, AL, AR, CO, DE, HI, IA, ID, MA, 
ME, MI, MO, MT, ND, NE, NV, OK, RI, TN, UT, VT, WA, and WV (23 states). 
 
 
 
 
 
 
Table 6. Relative Risks for Quit Attempts by Expansion and Time Period by Co-payment, US BRFSS 2003-
2015 
 Quit Attempts Co-payments 
 Overall Yes  No  
Expanded  RR (95% CI) RR (95% CI) RR (95% CI) 
    Pre-expansion (2003-
2009) 
Ref Ref Ref 
    Post-expansion (2011-
2015) 
1.04 (1.04 – 1.05) 1.03 (1.02 – 1.03) 1.07 (1.06 – 1.07) 
Non-expanded     
    Pre-expansion (2003-
2009) 
Ref Ref Ref 
    Post-expansion (2011-
2015)  
1.03 (1.02 – 1.03) 1.02 (1.02 – 1.03) 1.03 (1.03 – 1.04) 
Note: Relative risks were adjusted for sex, race, annual household income, educational status including interaction 
terms for expansion status and time periods of pre-and post-expansion using Proc Genmod. Excluded 2010 data as 
the wash-out period. 
Co-payments required for smoking cessation among states include: AK, CA, CO, DE, OA, IL, IN, KS, LA, MA, 
ME, MN, MS, MT, NC, ND, NE, NH, NV, OH, OK, OR, PA, SD, TX, UT, VA, VT, WI, WV, and, WY (31 states).  
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FIGURES  
Figure 1: Prevalence of current smoking in the expanded vs. non-expanded states – BRFSS, 
United States, 2003-2015 
 
 
Figure 2: Prevalence of adult smokers reporting a quit attempt during the previous year in 
the expanded vs. non-expanded states – BRFSS, United States, 2003-2015  
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Supplemental Tables 
Table 1: Relative Risks for Current Smoking and Quit Attempts by ACA Expansion Status by Age-Group, US 
BRFSS 2011-2017 
 Current smokers (%) Quit Attempts (%) 
 
Year 
 
2011-2013 
 
2015-2017 
 
2011-2013 
 
2015-2017 
Overall US     
     Expanded  128,687 (16.37) 107,521 (14.47) 72691 (57.16) 59957 (56.01) 
     Non-expanded  104,257 (16.84)  82846 (15.33) 59290 (57.90) 46852 (56.77) 
 RR =  0.994  
(0.994-0.995) 
RR = 1.016  
(1.016-1.017) 
RR = 1.006 
(1.006-1.007) 
RR = 1.011  
(1.011-1.011) 
18-49 years     
     Expanded  59302 (20.66) 45590 (18.10) 35801 (61.22) 27367 (60.27) 
     Non-expanded  46892 (21.58) 35803 (19.47) 28636 (62.37) 21983 (61.66) 
 RR = 0.996  
(0.996-0.997) 
RR = 1.035  
(1.035-1.036) 
RR =  1.015  
(1.014-1.015) 
RR = 1.023  
(1.022-1.023) 
50-79 years     
     Expanded  67045 (15.19) 59994 (13.89) 35893 (53.84) 31787 (53.20) 
     Non-expanded  55486 (15.81) 45477 (14.61) 29850 (54.46) 24212 (53.37) 
 RR = 0.992  
(0.991-0.992) 
RR = 0.997  
(0.996-0.997) 
RR =  0.997  
(0.997-0.998) 
RR = 1.0008  
(1.0005-1.001) 
>=80 years     
     Expanded  2340 (3.62) 1937 (3.24) 997 (42.50) 803 (41.78) 
     Non-expanded  1879 (3.42) 1566 (3.41) 804 (42.21) 657 (42.11) 
 RR = 1.005 
(1.001-1.008) 
RR = 1.006  
(1.004-1.008) 
RR = 0.968  
(0.964-0.973) 
RR = 0.995  
(0.993-0.997) 
Reference = Expanded; RR = rate ratio. RRs for age categories have been adjusted for sex, race, annual household income, 
and education status using Proc Genmod; excluding year 2014 as the washout period.  
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Table 2. Relative Risks for Current Smokers and Quit Attempts by Expansion and Time Period, US BRFSS 2011-2017 
                                               Overall Low Income (≤$20,000) 
 Current smoking* Quit Attempts* Current Smoking* Quit Attempts* 
 RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
Expand     
    Pre-expansion (2011-2013) Ref  Ref  Ref Ref 
    Post-expansion (2015-2017) 0.971  
(0.971-0.972) 
0.995  
(0.995-0.996) 
0.994  
(0.9932-0.9947) 
0.992  
(0.991-0.993) 
Non-expanded     
    Pre-expansion (2011-2013) Ref  Ref  Ref Ref 
    Post-expansion (2015-2017) 0.946  
(0.945-0.946) 
0.991  
(0.990-0.991) 
0.977  
(0.976-0.978) 
0.982  
(0.982-0.983) 
Note: Rate ratios were adjusted for sex, race, annual household income, educational status including interaction terms for 
expansion status and time periods of pre-and post-expansion using Proc Genmod 
P-value for expansion x time period interaction: *<0.0001 
Annual household income ≤ $20,000 
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CHAPTER 4 
 
CONCLUSION 
This capstone attempted to address environmental health and health policy issues using publicly 
available nationally representative data and epidemiologic methods. The purpose of this chapter 
is to briefly summarize the findings from the two diverse papers, discuss the public health 
implications of the two studies and to briefly summarize the limitations and recommendations.  
 
Summary of Findings 
 The first paper hypothesized that increasing blood Mn levels will be associated with 
higher prevalence of MI and stroke, while renal dysfunction prevalence will reduce with 
increasing blood Mn levels. In our findings, we found an increasing 10% non-significant 
increase of myocardial infarction and stroke. However, we did not find a significant reduction in 
the prevalence of renal dysfunction with increasing blood Mn levels. There were no differences 
in the association between blood Mn levels and myocardial infarction, stroke and renal 
dysfunction based on poverty income ratio.  
 Despite the lack of significant findings, there was a non-significant increasing trend for 
blood Mn levels and myocardial infarction and stroke. Due to the cross-sectional, we cannot 
establish a causal relationship based on our findings. However, both the outcomes and the 
exposure were measured using standard procedures from a nationally representative US 
population. This association needs to be further validated in prospective cohort studies to 
determine adverse effects of Mn on myocardial infarction and stroke.  
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The second paper focused to evaluate the impact of the Affordable Care Act (ACA) expansion 
on current smoking and quit-attempts in the expanded and the non-expanded US states, to 
evaluate the impact among low-income individuals; accounting for state-level barriers to 
smoking cessation services. Overall, during the pre-expansion period (2003-2009) current 
smoking was 2% higher in the non-expanded states compared to the expanded states, but it was 
lower 1% lower in the non-expanded states compared to the expanded states during the post-
expansion period (2011-2015). However, there was a 6% decline in current smoking in both the 
expanded and non-expanded states in the post- versus the pre-expansion period and a 4% 
increase in the quit-attempts. Moreover, there were no significant changes in current smoking 
rates among individuals with annual household incomes ≤$20,000; however, there was 4-5% 
increase in the quit-attempts in the post-expansion period compared to the pre-expansion period. 
Thus, following the ACA there were declines in current smoking rates both in the expanded and 
non-expanded states.  
The analyses from these two papers are beneficial to public health practitioners as they both 
attempt to find environmental and health policies that can reduce the burden of chronic diseases 
in the US.  
 
Implications for Public Health 
The role of public health is to protect and improve the health of the general population by health 
promotion, policy development, and disease prevention. Therefore, public health professionals 
aim to identify populations that are the most vulnerable. Since, clinical professions like doctors 
and nurses focus primarily on treating illnesses on individuals, public health works to reduce 
health disparities in the population. Thus, public health incorporates all aspects of an individual’s 
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well-being like social and physical environment, availability of health services, health behavior, 
and biology to address health issues in the population.  
 This capstone has attempted to identify the vulnerable and disparate populations using 
epidemiologic methods to assess biology, environmental, and health policy on the prevalence of 
chronic diseases and their risk factors. As practicing epidemiologists, it is our role to identify the 
primary risk factors and initiate the necessary health policies that can influence the health of a 
community and the general population. As we did find that certain policies help to reduce health 
disparities, we need to better on reducing barriers and administrative costs for the vulnerable 
populations that prevent access to timely preventive care.  
 The analyses of the two papers is timely as they address the environmental, biological, 
and health policy impact on risk factors that are associated with the onset of chronic diseases. 
Future research needs to evaluate implementation of policy and studies to prospectively assess 
the biomarkers that can reduce the cost of chronic diseases in the United States. 
 
 
 
 
